Aim. To determine the efficacy of AT1 receptor antagonist (valsartan) in decreasing of urinary excretion of albumin in normotensive patients with type 1 diabetes and incipient diabetic nephropathy (DN). Methods. This was a prospective, randomised, placebo-controlled study, which included 20 patients with insulin-dependent diabetes mellitus, mean age 25.15, and the duration of diabetes of 13.95 years. All the patients were normotensive, with persistent microalbuminuria (incipient phase of DN). Patients were randomly divided into two groups (10 patients each): valsartan group treated with 80 mg valsartan daily during 6 months, and the group treated with placebo during the same period. Both groups were similar and comparable concerning the obs...
textabstractBACKGROUND: Angiotensin-converting enzyme inhibitors have shown antiproteinuric ef...
Cilnidipine, an L-/N-type calcium channel blocker, dilates the efferent glomerular arterioles in an ...
Background/Aims: Immunoglobulin A nephropathy (IgAN) is a generally progressive disease, even in pat...
Aims Renin-angiotensin system blockers reduce the incidence and progression of microalbuminuria and ...
Aims: Renin-angiotensin system blockers reduce the incidence and progression of microalbuminuria ...
Aims: Renin-angiotensin system blockers reduce the incidence and progression of microalbuminuria ...
The effects of valsartan on the accumulation of circulating and renal advanced glycation end product...
shown antiproteinuric effects in normotensive and hypertensive diabetic patients. Angiotensin-recept...
Background: Angiotensin-converting enzyme inhibitors have shown antiproteinuric effects in normotens...
Background: Angiotensin-converting enzyme inhibitors have shown antiproteinuric effects in normotens...
Background: Angiotensin-converting enzyme inhibitors have shown antiproteinuric effects in normotens...
Background: Angiotensin-converting enzyme inhibitors have shown antiproteinuric effects in normotens...
Background: Angiotensin-converting enzyme inhibitors have shown antiproteinuric effects in normotens...
To examine the effect of low-dose losartan, an angiotensin II antagonist, on persistent microalbumin...
Aims To examine the effect of valsartan on kidney outcomes in patients with impaired glucose toleran...
textabstractBACKGROUND: Angiotensin-converting enzyme inhibitors have shown antiproteinuric ef...
Cilnidipine, an L-/N-type calcium channel blocker, dilates the efferent glomerular arterioles in an ...
Background/Aims: Immunoglobulin A nephropathy (IgAN) is a generally progressive disease, even in pat...
Aims Renin-angiotensin system blockers reduce the incidence and progression of microalbuminuria and ...
Aims: Renin-angiotensin system blockers reduce the incidence and progression of microalbuminuria ...
Aims: Renin-angiotensin system blockers reduce the incidence and progression of microalbuminuria ...
The effects of valsartan on the accumulation of circulating and renal advanced glycation end product...
shown antiproteinuric effects in normotensive and hypertensive diabetic patients. Angiotensin-recept...
Background: Angiotensin-converting enzyme inhibitors have shown antiproteinuric effects in normotens...
Background: Angiotensin-converting enzyme inhibitors have shown antiproteinuric effects in normotens...
Background: Angiotensin-converting enzyme inhibitors have shown antiproteinuric effects in normotens...
Background: Angiotensin-converting enzyme inhibitors have shown antiproteinuric effects in normotens...
Background: Angiotensin-converting enzyme inhibitors have shown antiproteinuric effects in normotens...
To examine the effect of low-dose losartan, an angiotensin II antagonist, on persistent microalbumin...
Aims To examine the effect of valsartan on kidney outcomes in patients with impaired glucose toleran...
textabstractBACKGROUND: Angiotensin-converting enzyme inhibitors have shown antiproteinuric ef...
Cilnidipine, an L-/N-type calcium channel blocker, dilates the efferent glomerular arterioles in an ...
Background/Aims: Immunoglobulin A nephropathy (IgAN) is a generally progressive disease, even in pat...